REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.01
-0.83 (-10.54%)
Mar 31, 2025, 1:37 PM EDT - Market open

REGENXBIO Statistics

Total Valuation

REGENXBIO has a market cap or net worth of $350.85 million. The enterprise value is $240.95 million.

Market Cap 350.85M
Enterprise Value 240.95M

Important Dates

The last earnings date was Thursday, March 13, 2025, after market close.

Earnings Date Mar 13, 2025
Ex-Dividend Date n/a

Share Statistics

REGENXBIO has 50.09 million shares outstanding. The number of shares has increased by 13.21% in one year.

Current Share Class 50.09M
Shares Outstanding 50.09M
Shares Change (YoY) +13.21%
Shares Change (QoQ) +0.14%
Owned by Insiders (%) 7.68%
Owned by Institutions (%) 75.99%
Float 41.16M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 4.65
Forward PS 1.50
PB Ratio 1.49
P/TBV Ratio 1.33
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.89
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.55.

Current Ratio 2.69
Quick Ratio 2.59
Debt / Equity 0.55
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -18.27

Financial Efficiency

Return on equity (ROE) is -79.49% and return on invested capital (ROIC) is -32.24%.

Return on Equity (ROE) -79.49%
Return on Assets (ROA) -27.79%
Return on Invested Capital (ROIC) -32.24%
Return on Capital Employed (ROCE) -63.74%
Revenue Per Employee $236,057
Profits Per Employee -$643,348
Employee Count 353
Asset Turnover 0.16
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -66.87% in the last 52 weeks. The beta is 1.35, so REGENXBIO's price volatility has been higher than the market average.

Beta (5Y) 1.35
52-Week Price Change -66.87%
50-Day Moving Average 7.39
200-Day Moving Average 9.87
Relative Strength Index (RSI) 44.00
Average Volume (20 Days) 980,919

Short Selling Information

The latest short interest is 6.05 million, so 12.08% of the outstanding shares have been sold short.

Short Interest 6.05M
Short Previous Month 6.28M
Short % of Shares Out 12.08%
Short % of Float 14.70%
Short Ratio (days to cover) 7.14

Income Statement

In the last 12 months, REGENXBIO had revenue of $83.33 million and -$227.10 million in losses. Loss per share was -$4.59.

Revenue 83.33M
Gross Profit 49.76M
Operating Income -231.25M
Pretax Income -241.23M
Net Income -227.10M
EBITDA -215.03M
EBIT -231.25M
Loss Per Share -$4.59
Full Income Statement

Balance Sheet

The company has $234.69 million in cash and $141.72 million in debt, giving a net cash position of $103.15 million or $2.06 per share.

Cash & Cash Equivalents 234.69M
Total Debt 141.72M
Net Cash 103.15M
Net Cash Per Share $2.06
Equity (Book Value) 259.65M
Book Value Per Share 5.24
Working Capital 174.81M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$173.13 million and capital expenditures -$2.44 million, giving a free cash flow of -$175.56 million.

Operating Cash Flow -173.13M
Capital Expenditures -2.44M
Free Cash Flow -175.56M
FCF Per Share -$3.51
Full Cash Flow Statement

Margins

Gross margin is 59.72%, with operating and profit margins of -277.51% and -272.54%.

Gross Margin 59.72%
Operating Margin -277.51%
Pretax Margin -272.54%
Profit Margin -272.54%
EBITDA Margin -258.05%
EBIT Margin -277.51%
FCF Margin n/a

Dividends & Yields

REGENXBIO does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -13.21%
Shareholder Yield n/a
Earnings Yield -66.00%
FCF Yield -51.02%

Analyst Forecast

The average price target for REGENXBIO is $32.89, which is 369.52% higher than the current price. The consensus rating is "Strong Buy".

Price Target $32.89
Price Target Difference 369.52%
Analyst Consensus Strong Buy
Analyst Count 9
Revenue Growth Forecast (5Y) 52.85%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

REGENXBIO has an Altman Z-Score of -1.89 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -1.89
Piotroski F-Score 5